The following topics are planned to be commented on during the call: Join the video meeting by clicking this link: https://meet.google.com/jmy-cdhn-wwo.You...
IBT has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company's drug...
Infant Bacterial Therapeutics AB (IBT) announces today that it has been granted a Notice of Allowance from the US Patent and Trademark Office (USPTO)...
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2024, among other things, the following was resolved: ContactsStaffan...
Message from the CEO IBT has successfully completed the recruitment of infants for our Phase III study (The Connection Study), which is the final clinical...
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be...